Li Kang Biomedical Balance Sheet Health
Financial Health criteria checks 6/6
Li Kang Biomedical has a total shareholder equity of NT$630.0M and total debt of NT$35.0M, which brings its debt-to-equity ratio to 5.6%. Its total assets and total liabilities are NT$827.0M and NT$197.0M respectively. Li Kang Biomedical's EBIT is NT$133.4M making its interest coverage ratio -50.4. It has cash and short-term investments of NT$301.0M.
Key information
5.6%
Debt to equity ratio
NT$35.00m
Debt
| Interest coverage ratio | -50.4x |
| Cash | NT$301.02m |
| Equity | NT$630.03m |
| Total liabilities | NT$196.97m |
| Total assets | NT$827.01m |
Recent financial health updates
Recent updates
Li Kang Biomedical (GTSM:6242) Has Some Way To Go To Become A Multi-Bagger
Apr 19
Is Li Kang Biomedical Co., Ltd. (GTSM:6242) A Smart Choice For Dividend Investors?
Mar 09Li Kang Biomedical Co., Ltd.'s (GTSM:6242) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?
Feb 09The Trends At Li Kang Biomedical (GTSM:6242) That You Should Know About
Jan 19We Think Li Kang Biomedical (GTSM:6242) Can Stay On Top Of Its Debt
Dec 29Three Things You Should Check Before Buying Li Kang Biomedical Co., Ltd. (GTSM:6242) For Its Dividend
Dec 08Financial Position Analysis
Short Term Liabilities: 6242's short term assets (NT$355.7M) exceed its short term liabilities (NT$109.7M).
Long Term Liabilities: 6242's short term assets (NT$355.7M) exceed its long term liabilities (NT$87.3M).
Debt to Equity History and Analysis
Debt Level: 6242 has more cash than its total debt.
Reducing Debt: 6242's debt to equity ratio has reduced from 12.4% to 5.6% over the past 5 years.
Debt Coverage: 6242's debt is well covered by operating cash flow (276.4%).
Interest Coverage: 6242 earns more interest than it pays, so coverage of interest payments is not a concern.